<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03170349</url>
  </required_header>
  <id_info>
    <org_study_id>2016-05</org_study_id>
    <nct_id>NCT03170349</nct_id>
  </id_info>
  <brief_title>The CLASP Study Edwards PASCAL TrAnScatheter Mitral Valve RePair System Study</brief_title>
  <acronym>CLASP</acronym>
  <official_title>The CLASP Study Edwards PASCAL TrAnScatheter Mitral Valve RePair System Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, performance and clinical outcomes of the&#xD;
      Edwards PASCAL Transcatheter Mitral Valve Repair (TMVr) System.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess the safety, performance and clinical outcomes of the&#xD;
      Edwards PASCAL Transcatheter Mitral Valve Repair (TMVr) System. This is a multi-center,&#xD;
      multi-national, prospective, single arm, safety, performance and clinical outcomes study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 27, 2017</start_date>
  <completion_date type="Anticipated">August 2025</completion_date>
  <primary_completion_date type="Actual">July 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of major adverse events (MAE) defined as cardiovascular mortality, stroke, myocardial infarction, new need for renal replacement therapy, severe bleeding and re-intervention for study device related complications at 30 days.</measure>
    <time_frame>The primary endpoint will be assessed at 30 days.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mitral regurgitation reduction</measure>
    <time_frame>30 days, 6 months, 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days , 6 months, 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent heart failure hospitalization</measure>
    <time_frame>30 days , 6 months, 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Six Minute Walk Test (6MWT) distance</measure>
    <time_frame>6 months and 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Mitral Valve Regurgitation</condition>
  <arm_group>
    <arm_group_label>Edwards PASCAL Transcatheter Mitral Valve Repair System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mitral Valve Repair</intervention_name>
    <description>Minimal Invasive Transcatheter Mitral Valve Repair</description>
    <arm_group_label>Edwards PASCAL Transcatheter Mitral Valve Repair System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated IRB/ethics committee approved study consent form prior to study&#xD;
             related procedures&#xD;
&#xD;
          -  Eighteen (18) years of age or older&#xD;
&#xD;
          -  New York Heart Association (NYHA) Functional Class II-IVa heart failure despite&#xD;
             optimal medical therapy&#xD;
&#xD;
          -  Candidacy for surgical mitral valve repair or replacement determined by Heart Team&#xD;
             evaluation&#xD;
&#xD;
          -  Clinically significant mitral regurgitation (moderate-to-severe or severe mitral&#xD;
             regurgitation) confirmed by transesophageal echocardiography (TEE) and transthoracic&#xD;
             echocardiography (TTE).&#xD;
&#xD;
          -  The primary regurgitant jet is non-commissural. If a secondary jet exists, it must be&#xD;
             considered clinically insignificant.&#xD;
&#xD;
          -  Mitral valve area (MVA) ≥ 4.0 cm² as measured by planimetry. If MVA by planimetry is&#xD;
             not measurable, pressure half-time measurement is acceptable.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient in whom a TEE is contraindicated or screening TEE is unsuccessful&#xD;
&#xD;
          -  Leaflet anatomy which may preclude PASCAL device implantation, proper device&#xD;
             positioning on the leaflets, or sufficient reduction in mitral regurgitation.&#xD;
&#xD;
          -  Mitral valve area (MVA) &lt; 4.0 cm² as measured by planimetry (If MVA by planimetry is&#xD;
             not measurable, PHT measurement is acceptable)&#xD;
&#xD;
          -  Echocardiographic evidence of intracardiac mass, thrombus, or vegetation&#xD;
&#xD;
          -  Physical evidence of right sided congestive heart failure and echocardiographic&#xD;
             evidence of severe right ventricular dysfunction&#xD;
&#xD;
          -  Concurrent medical condition with a life expectancy of less than 12 months in the&#xD;
             judgment of the Investigator&#xD;
&#xD;
          -  Patient is currently participating or has participated in another investigational drug&#xD;
             or device clinical study where the primary study endpoint was not reached at time of&#xD;
             enrollment&#xD;
&#xD;
          -  Patient is under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gideon Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrich Schafer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Hamburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Molly Szerlip, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Heart Hospital Baylor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Heart Hospital Baylor Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro North Hospital &amp; Health Service, The Prince Charles Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Chermside</state>
        <zip>QLD 4032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydney Local Health District, Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital, Providence Health Care Research Institute</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6E 1M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Michael Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B-1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Bonn, Medizinische Klinik II, Kardiologie</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hygeia Hospital</name>
      <address>
        <city>Athens</city>
        <zip>15123</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Rafaelle Hospital</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital, University Hospital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 26, 2017</study_first_submitted>
  <study_first_submitted_qc>May 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2017</study_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>July 28, 2021</submitted>
    <returned>August 20, 2021</returned>
    <submitted>September 14, 2021</submitted>
    <returned>October 8, 2021</returned>
    <submitted>November 2, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

